Literature DB >> 19300971

Muscle rupture caused by exacerbated spasticity in a patient with multiple sclerosis.

Robert Patejdl1, Alexander Winkelmann, Reiner Benecke, Uwe Klaus Zettl.   

Abstract

We report a case of muscle rupture caused by acute exacerbation of spasticity in a patient with primary chronic progressive multiple sclerosis (PPMS). A complete disruption of the adductor muscles was diagnosed by sonography and still reproducible in a follow-up three months after the clinical event. To our knowledge, this is the first case report of muscle rupture caused by spasticity in a patient with MS. In addition to the clinical case report we give a short overview of morphological and functional changes in spastic muscle and current standards of symptomatic therapy.

Entities:  

Mesh:

Year:  2008        PMID: 19300971     DOI: 10.1007/s00415-008-6021-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  13 in total

1.  Spastic muscle cells are shorter and stiffer than normal cells.

Authors:  Jan Fridén; Richard L Lieber
Journal:  Muscle Nerve       Date:  2003-02       Impact factor: 3.217

2.  Spasticity in multiple sclerosis.

Authors:  M P Barnes; R M Kent; J K Semlyen; K M McMullen
Journal:  Neurorehabil Neural Repair       Date:  2003-03       Impact factor: 3.919

Review 3.  Complete semimembranosus rupture following therapeutic stretching after a traumatic brain injury.

Authors:  S G Karen Chua; K H Kong
Journal:  Brain Inj       Date:  2006-06       Impact factor: 2.311

4.  Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society.

Authors:  T Henze; P Rieckmann; K V Toyka
Journal:  Eur Neurol       Date:  2006-09-08       Impact factor: 1.710

5.  Efficacy of mitoxantrone and intrathecal triamcinolone acetonide treatment in chronic progressive multiple sclerosis patients.

Authors:  Kerstin Hellwig; Sebastian Schimrigk; Carsten Lukas; Volker Hoffmann; Nils Brune; Horst Przuntek; Thomas Müller
Journal:  Clin Neuropharmacol       Date:  2006 Sep-Oct       Impact factor: 1.592

6.  Intrathecal versus systemic corticosteroids in the treatment of multiple sclerosis: results of a pilot study.

Authors:  R Heun; U Sliwka; H Rüttinger; K Schimrigk
Journal:  J Neurol       Date:  1992-01       Impact factor: 4.849

Review 7.  Structural and functional changes in spastic skeletal muscle.

Authors:  Richard L Lieber; Suzanne Steinman; Ilona A Barash; Hank Chambers
Journal:  Muscle Nerve       Date:  2004-05       Impact factor: 3.217

8.  Inferior mechanical properties of spastic muscle bundles due to hypertrophic but compromised extracellular matrix material.

Authors:  Richard L Lieber; Eva Runesson; Fredrik Einarsson; Jan Fridén
Journal:  Muscle Nerve       Date:  2003-10       Impact factor: 3.217

9.  Multiple sclerosis registry in Germany: results of the extension phase 2005/2006.

Authors:  Peter Flachenecker; Kristin Stuke; Wolfgang Elias; Matthias Freidel; Judith Haas; Dorothea Pitschnau-Michel; Sebastian Schimrigk; Uwe K Zettl; Peter Rieckmann
Journal:  Dtsch Arztebl Int       Date:  2008-02-15       Impact factor: 5.594

10.  Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients.

Authors:  Volker Hoffmann; Sebastian Schimrigk; Saida Islamova; Kerstin Hellwig; Carsten Lukas; Nils Brune; Dieter Pöhlau; Horst Przuntek; Thomas Müller
Journal:  J Neurol Sci       Date:  2003-07-15       Impact factor: 3.181

View more
  1 in total

1.  Effects of intrathecal triamincinolone-acetonide treatment in MS patients with therapy-resistant spasticity.

Authors:  F Kamin; P S Rommer; M Abu-Mugheisib; W Koehler; F Hoffmann; A Winkelmann; R Benecke; U K Zettl
Journal:  Spinal Cord       Date:  2014-09-16       Impact factor: 2.772

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.